Australia records more than 2,000 drug-induced deaths in a typical year — yet the public debate about drugs rarely engages with what is actually killing people. Pharmaceutical opioids kill more Australians than heroin. Methamphetamine deaths have more than doubled since the early 2010s. Synthetic opioids are emerging as a threat Australian authorities have never dealt with at scale. And alcohol — counted separately in government statistics — kills more than twice as many Australians as all other drugs combined. Here is what the AIHW data actually shows.
The AIHW's National Mortality Database is the primary source for drug-induced deaths in Australia. "Drug-induced deaths" is a specific classification — it captures deaths where the direct cause is attributed to drug use, primarily overdose, but excludes deaths where drug use is a contributing factor (such as drug-related road fatalities, long-term organ damage from substance use, or drug-related cancers). It also excludes alcohol, which the AIHW counts separately under a burden-of-disease framework.
With that definitional caveat stated, the headline figures from the most recent AIHW National Mortality Database data (2021) are as follows:
The comparison with alcohol is striking and consistently underappreciated. At approximately 4,500 deaths per year attributed to alcohol (the AIHW's Burden of Disease estimate, which uses a narrower alcohol-caused definition; the broader attributable-deaths figure used in our alcohol statistics analysis is around 5,500), alcohol kills more than twice as many Australians as all illicit and pharmaceutical drug deaths combined. Yet drug deaths receive a disproportionate share of political and media attention. This does not mean drug-induced deaths are not serious — 1,900 preventable deaths per year is an enormous toll — but the framing matters when policy resources are being allocated.
The 1,700–2,000 range that drug-induced deaths have occupied over recent years represents a significant increase from the 1990s baseline, when heroin-era deaths pushed figures in a different pattern. The current landscape is structurally different from the peak of Australia's heroin epidemic in the late 1990s and early 2000s: the drugs killing Australians now are predominantly pharmaceutical in origin, and the demographics of victims are older.
Opioids — substances that act on opioid receptors in the brain and body — account for the majority of drug-induced deaths in Australia. The critical distinction is between pharmaceutical opioids (prescribed medicines obtained legally or through diversion) and illicit opioids (primarily heroin, plus emerging synthetic opioids). The pharmaceutical category is now the larger of the two.
Australia has a relatively high rate of opioid prescribing by international standards. Medicines including oxycodone (OxyContin and generics), fentanyl patches, morphine, hydromorphone, and — until 2018 — over-the-counter codeine products were widely available through the healthcare system. The AIHW data shows that pharmaceutical opioids account for the majority of opioid deaths in Australia, with oxycodone and fentanyl featuring prominently in toxicology findings.
The pattern of pharmaceutical opioid deaths differs from illicit drug deaths in important ways. Victims tend to be older — concentrated in the 45–64 age bracket rather than the 25–34 bracket more typical of heroin deaths. Many involve chronic pain patients whose prescriptions have escalated over time. A significant proportion involve multiple prescribed medicines taken simultaneously, which leads directly to the polysubstance discussion in the next section.
Codeine rescheduling (February 2018): The TGA moved codeine-containing products — previously available over the counter at pharmacies — to Schedule 4 (prescription only) in February 2018. This was a significant regulatory intervention. AIHW data shows a reduction in codeine-specific deaths in the years following rescheduling. However, the evidence also suggests some migration: patients who previously used codeine products shifted to stronger prescription opioids, and the overall opioid death rate did not fall proportionately. The rescheduling was the right intervention; its effects were partially offset by prescribing patterns for stronger opioids.
Heroin — the drug most people associate with overdose deaths — is now a minority of Australia's opioid death burden. This is partly a supply story: Australia's heroin drought of the early 2000s restructured the illicit drug market in ways that were never fully reversed. But it is also a pharmaceutical story: the availability of diverted prescription opioids has reduced the relative role of heroin in the market.
The emerging and more alarming trend in illicit opioids is the growth of synthetic opioids — substances including illicitly manufactured fentanyl and its analogues, and more recently nitazenes (a class of synthetic opioid with no approved medical use). The Australian Criminal Intelligence Commission (ACIC) has flagged synthetic opioids as an emerging high-priority risk for Australian drug markets. Australia has so far been largely spared the fentanyl crisis that has devastated North America — where fentanyl now accounts for the vast majority of overdose deaths — but ACIC's intelligence suggests growing availability and a realistic risk of market penetration accelerating.
Synthetic opioids present a qualitatively different risk from heroin or pharmaceutical opioids. Illicitly manufactured fentanyl is approximately 50–100 times more potent than morphine; certain nitazene compounds are more potent still. Because they are manufactured in clandestine laboratories rather than regulated pharmaceutical plants, doses are inconsistent. A single tablet or powder can contain a lethal dose without the user's knowledge. The harm-reduction implication — naloxone availability, drug checking services, and supervised consumption — is discussed below.
While opioid deaths have attracted the most sustained policy attention, stimulant deaths — particularly methamphetamine — represent the fastest-growing category in Australia's drug mortality data.
Methamphetamine-related deaths have roughly doubled since the early 2010s, rising from approximately 150 per year to around 350 per year by the most recent AIHW data. This trajectory mirrors the well-documented shift in Australia's methamphetamine market toward high-purity crystal methamphetamine (commonly called ice), which began accelerating around 2013–2015 as trafficking networks sourcing from overseas suppliers established themselves.
Methamphetamine deaths are not exclusively overdose deaths in the traditional sense. While acute toxicity does cause deaths, methamphetamine also causes cardiac deaths (arrhythmias, myocardial infarction) and neurological deaths that may occur months or years after the acute period of heavy use. This means the mortality burden of methamphetamine use is likely underestimated in drug-induced deaths figures that focus on proximate cause.
Regional concentration: Methamphetamine deaths are not uniformly distributed across Australia. ACIC drug use monitoring data and state health data consistently show elevated methamphetamine involvement in regional and rural areas — including mining communities in Western Australia and Queensland, regional New South Wales and Victoria, and coastal areas that historically showed lower rates than capital cities. This geographic pattern matters for treatment service allocation: regional Australia has significantly fewer treatment options per capita than urban centres.
The methamphetamine death trend also has an age dimension. While the stereotyped methamphetamine user is young, AIHW data shows methamphetamine deaths increasingly concentrated in older users — people who began using in the 1990s and 2000s and are now experiencing the long-term cardiovascular and neurological consequences. This is a different cohort from the ice users who entered the market post-2013.
Cocaine accounts for fewer than 100 drug-induced deaths per year in Australia — a small fraction of the opioid or methamphetamine toll — but the trend is upward and the mechanism of death differs from other drug categories. The primary cause of cocaine death is cardiac: acute myocardial infarction (heart attack) or arrhythmia, often in people with no diagnosed pre-existing heart condition. This gives cocaine deaths a particular demographic profile — younger users, often male, who would not otherwise be considered high-risk.
Wastewater epidemiology data, which the ACIC and state agencies use to measure drug use at population level without relying on self-report, consistently shows rising cocaine use in Australian capital cities. Sydney and Melbourne wastewater readings have trended upward for cocaine over the past decade. The cocaine death toll, while currently small, is likely to rise if use continues to increase.
One of the most important and least publicly understood features of drug mortality data is that the majority of drug-induced deaths involve more than one substance. Toxicology findings in overdose deaths routinely show two, three, or more psychoactive substances — often a combination that individually would not be fatal but in combination produces respiratory depression or cardiac failure.
The most lethal combinations in Australian drug-death data include:
Naloxone availability: Naloxone is a medicine that rapidly reverses opioid overdose — administered as a nasal spray or injection, it can prevent death if given quickly. The TGA rescheduled naloxone to Schedule 3 (pharmacist-only, no prescription required) in 2016, and some states have since moved to make it available without charge. Despite this, community uptake remains lower than harm reduction advocates consider adequate. Expanding naloxone access to people who use opioids, their families, and first responders is one of the best-evidenced interventions for reducing opioid deaths — but coverage remains patchy, particularly in regional areas.
Drug-induced death rates vary across Australia's states and territories, reflecting differences in drug market structure, prescribing patterns, population demographics, and the availability of harm reduction services.
Australia has two operating supervised injecting facilities: the Sydney MSIC (Kings Cross, operating since 2001) and the North Richmond supervised injecting room in Melbourne (operating since 2018). Both allow people to inject pre-obtained drugs under the supervision of health professionals, with immediate access to resuscitation if an overdose occurs.
The Sydney MSIC has a particularly robust evidence base. Over more than two decades of operation, the facility has overseen more than 1.5 million injections — and recorded zero on-site overdose deaths. This is not because overdoses don't happen: staff have managed thousands of overdose events. The zero-death outcome reflects the fact that trained staff with naloxone and resuscitation equipment are present when overdoses occur, meaning they are reversible. A study published in the Medical Journal of Australia found that the MSIC was associated with a 35% reduction in ambulance calls for overdose in the immediate vicinity.
Internationally, more than 100 supervised consumption facilities now operate across Europe, Canada, and Australia. The evidence base across these facilities is consistent: they reduce overdose deaths in the surrounding area, reduce ambulance call-outs, connect people who use drugs with treatment and health services, and do not increase drug use or drug-related crime in surrounding areas. The last finding — that facilities do not increase local drug use — has been robust across many different urban contexts.
Harm reduction is not only about supervised consumption. Other evidence-based interventions include needle and syringe programmes (which reduce blood-borne virus transmission and have been operating in Australia since the late 1980s), naloxone distribution, drug checking services (legal in the ACT since 2023 and operated at some festivals), and opioid agonist therapy (methadone and buprenorphine, which reduce illicit opioid use and overdose risk in people with opioid dependence).
The AIHW National Mortality Database drug-induced deaths count, while the best available measure, undercounts the full mortality burden of drug use in Australia in several ways:
For the broader context on how drug issues intersect with crime and the justice system, see our analysis of crime statistics across Australia. The economic costs of drug use — treatment, law enforcement, productivity loss — are significant, as explored in our coverage of Australia's cost pressures in 2026. Official data is available directly from the AIHW National Mortality Database, the ACIC's Illicit Drug Data Report, and the ABS Causes of Death publication.
How many people die from drugs in Australia each year?
The AIHW National Mortality Database recorded approximately 1,900 drug-induced deaths in 2021 — a figure that has fluctuated between 1,700 and 2,000 over recent years. This count excludes alcohol, which causes a further 4,500+ deaths per year and is separately categorised, and road fatalities where drug impairment is a contributing factor. The total drug and alcohol mortality burden in Australia is therefore substantially higher than the drug-induced deaths figure alone suggests.
What is the most common cause of drug death in Australia?
Opioids are the principal drug in 60–70% of drug-induced deaths in Australia, according to AIHW data. Pharmaceutical opioids — including oxycodone, fentanyl, and morphine — account for a larger share of opioid deaths than illicit opioids such as heroin. This reflects Australia's relatively high rate of opioid prescribing compared to other comparable countries, and the migration of some patients from codeine (rescheduled to prescription-only in 2018) to stronger opioid products.
Are drug deaths rising or falling in Australia?
The overall total has been relatively stable at 1,700–2,000 drug-induced deaths per year. Within that total, pharmaceutical opioid deaths stabilised following the TGA's codeine rescheduling in February 2018, though stronger opioid deaths remain elevated. Methamphetamine deaths have risen sharply since 2015, roughly doubling from around 150 per year to 350+. Synthetic opioids — fentanyl analogues and nitazenes — are an emerging threat that ACIC flags as a high-priority risk for Australian markets, and could substantially change the mortality picture if they achieve significant market penetration.
Which state has the most drug deaths in Australia?
New South Wales records the highest absolute number of drug-induced deaths, reflecting its status as Australia's most populous state. On a per-capita basis, the ACT and Tasmania often record above-average drug-induced death rates. The Northern Territory records the highest overall substance harm per capita — encompassing alcohol, drugs, and polysubstance — though small population size makes year-to-year NT figures volatile and difficult to compare with larger states.
What drugs cause the most deaths in Australia?
In order of deaths caused: (1) Pharmaceutical opioids — oxycodone, fentanyl patches, morphine; (2) Illicit opioids — heroin plus emerging synthetic opioids including fentanyl analogues and nitazenes; (3) Methamphetamine — approximately 350 deaths per year, rising sharply since 2015; (4) Benzodiazepines — usually in combination with opioids rather than as sole cause; (5) Cocaine — under 100 deaths per year but rising, primarily via cardiac mechanism in younger users. Alcohol causes 4,500+ deaths per year separately and is not included in the drug-induced deaths count.
TaxPit tracks what's actually happening in Australia — government data, no spin. Check the live dashboard for the latest indicators.
View the Dashboard →